Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Intestinal microbiota–host immune system interaction
- Molecular classification
- Other (complex biological network/ecological unit; not classifiable as receptor, enzyme, transporter, transcription factor, etc.)
01
Overview
The intestinal microbiota–host immune system interaction is a complex, dynamic network essential for the health of the host. The gut microbiome trains and tunes both innate and adaptive immunity—regulating local and systemic inflammatory responses and ensuring the integrity of the intestinal barrier. This interplay affects susceptibility to infections, autoimmune disorders, allergies, and even neuroimmune and metabolic diseases. Disruption of the microbial community or immune functions leads to a wide range of pathologies, making this interaction a key area for therapeutic intervention through microbiome modulation, though not a classical drug target itself. Canonical therapeutic targets within this system include specific cytokines, cell surface receptors, and microbial metabolites, rather than the system as a whole.
- Other names
- gut microbiota–immune crosstalkgut-immune axismicrobiota–immune interactiongut microbiome–immune system interaction
02
Mechanism of action
Modulation of microbial composition to restore or maintain immune homeostasis Enhancement or suppression of immune responses by altering microbiota-derived metabolites, immune cell programming, or cytokine profiles Barrier protection or restoration via tight junction and mucosal integrity
03
Biological functions
Immune system development and training (innate and adaptive immunity)Regulation of intestinal barrier integrity and permeabilityProduction and modulation of cytokines and chemokinesShaping B cell and T cell lineages, especially regulatory T cells (Treg), Th1/Th17/Th2 responses, and IgA/IgG/IgE productionMaintenance of host-microbe symbiosis and homeostasis
04
Disease associations
Inflammatory bowel diseases (IBD)Autoimmune disorders (e.g., type 1 diabetes, allergies)Infections (local and systemic)Metabolic and neuroimmune disorders (via the gut-brain axis)Cancer (as a modifier of inflammation and immune surveillance)
05
Safety considerations
Unintended immune dysregulation (increased infection, autoimmunity, allergic responses)Risks linked with fecal microbiota transplantation (infection, transfer of undesirable traits)Off-target effects due to broad intervention in a complex ecosystemEmergence of pathogenic bacteria or loss of beneficial species
06
Interacting drugs
Antibiotics
4 more in the full profile.
07
Biomarkers
Microbial taxa abundance and diversityImmune cell populations (e.g., Tregs, Th17 cells)Cytokine and chemokine profiles (e.g., IL-1β, IFN-γ)Secretory IgA levelsBiomarkers of barrier dysfunction (e.g., zonulin)
Beyond the preview
Go deeper on Intestinal microbiota–host immune system interaction.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Intestinal microbiota–host immune system interaction.